SULT1A1 rs9282861 polymorphism-a potential modifier of efficacy of the systemic adjuvant therapy in breast cancer?

详细信息    查看全文

• 作者：Maria Tengstr?m (1) (2) (3)
  Arto Mannermaa (3) (4)
  Veli-Matti Kosma (3) (4)
  Ari Hirvonen (5)
  Vesa Kataja (1) (2) (3)
  
• 刊名：BMC Cancer
• 出版年：2012
• 出版时间：December 2012
• 年：2012
• 卷：12
• 期：1
• 全文大小：238KB
• 参考文献：1. Goldhirsch A, Ingle JN, Gelber RD, Coates AS, Thurlimann B, Senn HJ, Panel members: Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2009. / Ann Oncol 2009,20(8):1319-329. CrossRef
  2. Early Breast Cancer Trialists' Collaborative Group (EBCTCG), Davies C, Godwin J, Gray R, Clarke M, Cutter D, Darby S, McGale P, Pan HC, Taylor C, Wang YC, Dowsett M, Ingle J, Peto R: Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. / Lancet 2011,378(9793):771-84.
  3. Early Breast Cancer Trialists' Collaborative Group (EBCTCG): Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group. / Lancet 1998,351(9114):1451-467. CrossRef
  4. Deitcher SR, Gomes MP: The risk of venous thromboembolic disease associated with adjuvant hormone therapy for breast carcinoma: a systematic review. / Cancer 2004,101(3):439-49. CrossRef
  5. Lim YC, Desta Z, Flockhart DA, Skaar TC: Endoxifen (4-hydroxy-N-desmethyl-tamoxifen) has anti-estrogenic effects in breast cancer cells with potency similar to 4-hydroxy-tamoxifen. / Cancer Chemother Pharmacol 2005,55(5):471-78. CrossRef
  6. Nishiyama T, Ogura K, Nakano H, Ohnuma T, Kaku T, Hiratsuka A, Muro K, Watabe T: Reverse geometrical selectivity in glucuronidation and sulfation of cis- and trans-4-hydroxytamoxifens by human liver UDP-glucuronosyltransferases and sulfotransferases. / Biochem Pharmacol 2002,63(10):1817-830. CrossRef
  7. Raftogianis RB, Wood TC, Weinshilboum RM: Human phenol sulfotransferases SULT1A2 and SULT1A1: genetic polymorphisms, allozyme properties, and human liver genotype-phenotype correlations. / Biochem Pharmacol 1999,58(4):605-16. CrossRef
  8. Nowell S, Sweeney C, Winters M, Stone A, Lang NP, Hutchins LF, Kadlubar FF, Ambrosone CB: Association between sulfotransferase 1A1 genotype and survival of breast cancer patients receiving tamoxifen therapy. / J Natl Cancer Inst 2002,94(21):1635-640. CrossRef
  9. Choi JY, Lee KM, Park SK, Noh DY, Ahn SH, Chung HW, Han W, Kim JS, Shin SG, Jang IJ, Yoo KY, Hirvonen A, Kang D: Genetic polymorphisms of SULT1A1 and SULT1E1 and the risk and survival of breast cancer. / Cancer Epidemiol Biomarkers Prev 2005,14(5):1090-095. CrossRef
  10. Knechtel G, Hofmann G, Gerger A, Renner W, Langsenlehner T, Szkandera J, Wolf G, Samonigg H, Krippl P, Langsenlehner U: Analysis of common germline polymorphisms as prognostic factors in patients with lymph node-positive breast cancer. / J Cancer Res Clin Oncol 2010,136(12):1813-819. CrossRef
  11. Wegman P, Vainikka L, Stal O, Nordenskjold B, Skoog L, Rutqvist LE, Wingren S: Genotype of metabolic enzymes and the benefit of tamoxifen in postmenopausal breast cancer patients. / Breast Cancer Res 2005,7(3):R284-R290. CrossRef
  12. Bonadonna G, Brusamolino E, Valagussa P, Rossi A, Brugnatelli L, Brambilla C, De Lena M, Tancini G, Bajetta E, Musumeci R, Veronesi U: Combination chemotherapy as an adjuvant treatment in operable breast cancer. / N Engl J Med 1976,294(8):405-10. CrossRef
  13. Bonadonna G, Moliterni A, Zambetti M, Daidone MG, Pilotti S, Gianni L, Valagussa P: 30 years' follow up of randomised studies of adjuvant CMF in operable breast cancer: cohort study. / BMJ 2005,330(7485):217. CrossRef
  14. De Laurentiis M, Cancello G, D'Agostino D, Giuliano M, Giordano A, Montagna E, Lauria R, Forestieri V, Esposito A, Silvestro L, Pennacchio R, Criscitiello C, Montanino A, Limite G, Bianco AR, De Placido S: Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials. / J Clin Oncol 2008,26(1):44-3. CrossRef
  15. Pestalozzi B, Castiglione M, ESMO Guidelines Working Group, Primary breast cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up. / Ann Oncol 2008,19(Suppl 2):ii7-ii10. CrossRef
  16. Zhang J, Tian Q, Yung Chan S, Chuen Li S, Zhou S, Duan W, Zhu YZ: Metabolism and transport of oxazaphosphorines and the clinical implications. / Drug Metab Rev 2005,37(4):611-03. CrossRef
  17. Xie HJ, Yasar U, Lundgren S, Griskevicius L, Terelius Y, Hassan M, Rane A: Role of polymorphic human CYP2B6 in cyclophosphamide bioactivation. / Pharmacogenomics J 2003,3(1):53-1. CrossRef
  18. Ren S, Yang JS, Kalhorn TF, Slattery JT: Oxidation of cyclophosphamide to 4-hydroxycyclophosphamide and deschloroethylcyclophosphamide in human liver microsomes. / Cancer Res 1997,57(19):4229-235.
  19. Griskevicius L, Yasar U, Sandberg M, Hidestrand M, Eliasson E, Tybring G, Hassan M, Dahl ML: Bioactivation of cyclophosphamide: the role of polymorphic CYP2C enzymes. / Eur J Clin Pharmacol 2003,59(2):103-09.
  20. Sweeney C, Ambrosone CB, Joseph L, Stone A, Hutchins LF, Kadlubar FF, Coles BF: Association between a glutathione S-transferase A1 promoter polymorphism and survival after breast cancer treatment. / Int J Cancer 2003,103(6):810-14. CrossRef
  21. Sweeney C, McClure GY, Fares MY, Stone A, Coles BF, Thompson PA, Korourian S, Hutchins LF, Kadlubar FF, Ambrosone CB: Association between survival after treatment for breast cancer and glutathione S-transferase P1 Ile105Val polymorphism. / Cancer Res 2000,60(20):5621-624.
  22. Mitrunen K, Jourenkova N, Kataja V, Eskelinen M, Kosma VM, Benhamou S, Vainio H, Uusitupa M, Hirvonen A: Glutathione S-transferase M1, M3, P1, and T1 genetic polymorphisms and susceptibility to breast cancer. / Cancer Epidemiol Biomarkers Prev 2001,10(3):229-36.
  23. Sillanpaa P, Kataja V, Eskelinen M, Kosma VM, Uusitupa M, Vainio H, Mitrunen K, Hirvonen A: Sulfotransferase 1A1 genotype as a potential modifier of breast cancer risk among premenopausal women. / Pharmacogenet Genomics 2005,15(10):749-52. CrossRef
  24. Hartikainen JM, Kataja V, Pirskanen M, Arffman A, Ristonmaa U, Vahteristo P, Ryynanen M, Heinonen S, Kosma VM, Mannermaa A: Screening for BRCA1 and BRCA2 mutations in Eastern Finnish breast/ovarian cancer families. / Clin Genet 2007,72(4):311-20. CrossRef
  25. Engelke CE, Meinl W, Boeing H, Glatt H: Association between functional genetic polymorphisms of human sulfotransferases 1A1 and 1A2. / Pharmacogenetics 2000,10(2):163-69. CrossRef
  26. Nowell SA, Ahn J, Rae JM, Scheys JO, Trovato A, Sweeney C, MacLeod SL, Kadlubar FF, Ambrosone CB: Association of genetic variation in tamoxifen-metabolizing enzymes with overall survival and recurrence of disease in breast cancer patients. / Breast Cancer Res Treat 2005,91(3):249-58. CrossRef
  27. Wegman P, Elingarami S, Carstensen J, Stal O, Nordenskjold B, Wingren S: Genetic variants of CYP3A5, CYP2D6, SULT1A1, UGT2B15 and tamoxifen response in postmenopausal patients with breast cancer. / Breast Cancer Res 2007,9(1):R7. CrossRef
  28. Lien EA, Solheim E, Lea OA, Lundgren S, Kvinnsland S, Ueland PM: Distribution of 4-hydroxy-N-desmethyltamoxifen and other tamoxifen metabolites in human biological fluids during tamoxifen treatment. / Cancer Res 1989,49(8):2175-183.
  29. Sun D, Chen G, Dellinger RW, Duncan K, Fang JL, Lazarus P: Characterization of tamoxifen and 4-hydroxytamoxifen glucuronidation by human UGT1A4 variants. / Breast Cancer Res 2006,8(4):R50. CrossRef
  30. Sun D, Sharma AK, Dellinger RW, Blevins-Primeau AS, Balliet RM, Chen G, Boyiri T, Amin S, Lazarus P: Glucuronidation of active tamoxifen metabolites by the human UDP glucuronosyltransferases. / Drug Metab Dispos 2007,35(11):2006-014. CrossRef
  31. Dehal SS, Kupfer D: CYP2D6 catalyzes tamoxifen 4-hydroxylation in human liver. / Cancer Res 1997,57(16):3402-406.
  32. Schroth W, Goetz MP, Hamann U, Fasching PA, Schmidt M, Winter S, Fritz P, Simon W, Suman VJ, Ames MM, Safgren SL, Kuffel MJ, Ulmer HU, Bolander J, Strick R, Beckmann MW, Koelbl H, Weinshilboum RM, Ingle JN, Eichelbaum M, Schwab M, Brauch H: Association between CYP2D6 polymorphisms and outcomes among women with early stage breast cancer treated with tamoxifen. / JAMA 2009,302(13):1429-436. CrossRef
  33. Glatt H: Sulfotransferases in the bioactivation of xenobiotics. / Chem Biol Interact 2000,129(1-):141-70. CrossRef
  34. Jin Y, Desta Z, Stearns V, Ward B, Ho H, Lee KH, Skaar T, Storniolo AM, Li L, Araba A, Blanchard R, Nguyen A, Ullmer L, Hayden J, Lemler S, Weinshilboum RM, Rae JM, Hayes DF, Flockhart DA: CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment. / J Natl Cancer Inst 2005,97(1):30-9. CrossRef
  35. The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1471-2407/12/257/prepub
  
• 作者单位：Maria Tengstr?m (1) (2) (3)
  Arto Mannermaa (3) (4)
  Veli-Matti Kosma (3) (4)
  Ari Hirvonen (5)
  Vesa Kataja (1) (2) (3)
  
  1. Cancer Center, Kuopio University Hospital, P.O.BOX 1777, 70211, Kuopio, Finland
  2. Department of Oncology, Vaasa Central Hospital, Hietalahdenkatu 2-4, 65130, Vaasa, Finland
  3. Institute of Clinical Medicine, Pathology; Biocenter Kuopio; Cancer Center of Eastern Finland, University of Eastern Finland, Yliopistonranta 1C, 70210, Kuopio, Finland
  4. Imaging Center, Pathology, Kuopio University Hospital, P.O.BOX 1777, 70211, Kuopio, Finland
  5. Finnish Institute of Occupational Health, Topeliuksenkatu 41 a A, 00250, Helsinki, Finland
  
• ISSN：1471-2407

文摘

Background Sulfotransferase 1A1 (SULT1A1) participates in the elimination of 4-hydroxy-tamoxifen (4-OH-TAM), which is one of the major active metabolites of tamoxifen (TAM). Homozygous SULT1A1 variant allele genotype has been associated with lower catalytic activity and thermostability of the enzyme. Previous clinical studies suggest that the SULT1A1 rs9282861 polymorphism may influence the survival of breast cancer patients treated with TAM in the adjuvant setting. We investigated the effect of rs9282861 genotypes on the survival of Finnish breast cancer patients treated with adjuvant chemotherapy or TAM. Methods The rs9282861 genotypes of 412 Finnish breast cancer patients with early breast cancer were identified by using PCR-RFLP method. Seventy six patients were treated with adjuvant cyclophosphamide based chemotherapy only, 65 patients received adjuvant TAM, and four patients were treated with both adjuvant chemotherapy and TAM. Overall long-term survival (OS), breast cancer specific survival (BCSS), and relapse-free survival (RFS) by rs9282861 genotypes were evaluated by the Kaplan-Meier method and Cox regression analysis. Results The multivariate analysis of 145 patients receiving either adjuvant TAM or chemotherapy showed a statistically significantly improved OS in patients with the rs9282861 homozygous variant AA genotype (hazard ratio [HR] = 0.50, 95% confidence interval [CI] = 0.29-0.88, P = 0.015). In the separate analyses of patients receiving only chemotherapy or adjuvant TAM, there were no statistically significant differences in survival. Conclusions In this prospective study, we observed a previously unreported association between the SULT1A1 rs9282861 genotype and OS of breast cancer patients treated with adjuvant chemotherapy or TAM. This novel finding suggests that the rs9282861 polymorphism modifies the long-term clinical outcome of patients receiving adjuvant TAM or chemotherapy.